Trevena Advances NDA Resubmission Activities for Oliceridine
28 août 2019 16h01 HE
|
Trevena Inc.
— Completed enrollment in healthy volunteer QT study, topline data expected in Q4 2019 — — Completed characterization of inactive metabolite — — Remains on track to resubmit NDA in Q1 2020 — ...
Trevena Reports Second Quarter 2019 Results
07 août 2019 07h00 HE
|
Trevena Inc.
— Enrollment for healthy volunteer QT study ongoing, topline data on schedule for Q4 2019 readout — — Company remains on track to resubmit NDA for oliceridine in Q1 2020 — — Cash runway as...
Trevena to Report Second Quarter 2019 Results on August 7, 2019
31 juil. 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., July 31, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Appoints Barry Shin as Chief Financial Officer
27 juin 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of APOLLO-2 Results in Pain Practice
24 juin 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Initiation of Healthy Volunteer Study for Oliceridine
20 juin 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., June 20, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN) (“Trevena” or the “Company”), a biopharmaceutical company focused on the development and commercialization of novel...
Trevena to Participate in Upcoming Conferences in June 2019
29 mai 2019 16h01 HE
|
Trevena Inc.
CHESTERBROOK, Pa., May 29, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients...
Trevena Reports First Quarter 2019 Results
10 mai 2019 07h00 HE
|
Trevena Inc.
— Company announces receipt of FDA feedback on healthy volunteer study protocol and analysis plan for oliceridine — – Study on track to initiate by end of June – Company to host conference call...
Trevena Reports Fourth Quarter and Full Year 2018 Results
13 mars 2019 07h00 HE
|
Trevena Inc.
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to host conference call...
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
11 mars 2019 07h00 HE
|
Trevena Inc.
CHESTERBROOK, Pa., March 11, 2019 (GLOBE NEWSWIRE) -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of innovative treatment options that...